SmithKline Beecham
GSK Invests $800 Million in Pennsylvania Site Expansion to Boost Vaccine and Medicine Production
GSK, Pennsylvania, manufacturing expansion, vaccine production, medicine manufacturing, $800 million investment
GSK and Cambridge University Collaborate on $65M Research Initiative to Combat Immune-Related Kidney and Lung Diseases
GSK, Cambridge University, Immune-related diseases, Kidney diseases, Lung diseases, Research collaboration, $65M deal
GSK, Sanofi, and CSL Secure $72 Million BARDA Funding to Enhance Bird Flu Vaccine Supply
BARDA funding, bird flu vaccine, GSK, Sanofi, CSL, vaccine supply, public health
GSK Advances Co-Administration of RSV and Shingles Vaccines with Positive Phase III Data
GSK, RSV vaccine, Shingles vaccine, Arexvy, Shingrix, co-administration, Phase III data, adult immunization
GSK’s Zejula Fails to Meet Overall Survival Goal in First-Line Ovarian Cancer, Combination Therapy Disappoints
Zejula, niraparib, GSK, ovarian cancer, first-line treatment, overall survival, combination therapy, FDA, restriction, second-line maintenance
iTeos-GSK’s TIGIT Combination Demonstrates Superior Tumor Shrinkage in Phase 2 Trial
iTeos Therapeutics, GSK, TIGIT, EOS-448, Jemperli, Phase 2 trial, tumor shrinkage, immuno-oncology, cancer treatment
GSK Advances mRNA Flu Vaccine to Late-Stage Clinical Development Following Positive Phase II Results
GSK, mRNA flu vaccine, phase II results, late-stage clinical development, influenza A and B strains, vaccine efficacy, safety profile.
GSK’s Therapeutic Herpes Vaccine Fails to Meet Efficacy Objective in Phase I/II Trial
GSK, therapeutic herpes vaccine, herpes simplex virus, HSV, vaccine failure, clinical trial
GSK Abandons HSV Vaccine Development After Phase 2 Failure, Paving Way for Moderna and BioNTech
GSK, HSV vaccine, phase 2 failure, Moderna, BioNTech, mRNA vaccines, herpes simplex virus
GSK to Close UK Antibiotic Factory in Ulverston Following Sandoz Contract Termination
GSK, Ulverston, antibiotic factory, Sandoz contract, closure, job losses